Precision oncology accelerates development and improves results
At Novartis Oncology, we are a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes.
Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways:
- Identify pathways most commonly associated with cancer
- Screen compounds to identify ones with greatest potential to impact pathway
- Identify biomarkers and create diagnostic tools
- Target patients most likely to benefit from therapy
Thanks to this approach, the Novartis Oncology Pipeline is one of the strongest and most productive pipelines in the industry. The recent acquisition of the GSK oncology portfolio strengthens our industry-leading pipeline in precision cancer treatment and brings exciting potential to the development of combination regimens.